文献速递细菌感染、耐药与抗菌药物

多药耐药革兰阴性菌感染儿科患者中多黏菌素B的群体药代动力学与临床结局

Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

该研究纳入19例接受静脉多黏菌素B(1.33-2.53 mg/kg/天)的儿科患者,中位年龄12.5岁,建立二室群体药代动力学模型并评估疗效与肾毒性。临床成功14/19例(73.7%),仅1例发生急性肾损伤,28天死亡率10.5%(2/19)。稳态暴露为36.97±9.84 mg·h/L,低于50-100 mg·h/L的治疗暴露;当MIC<0.5 mg/L时,1.5-3.0 mg/kg/天剂量的靶标 attainment 概率超过90%。

要点

  • 体重是多黏菌素B清除率的显著协变量。
  • 临床成功14/19例(73.7%),28天死亡率10.5%(2/19)。
  • 当MIC<0.5 mg/L时,1.5-3.0 mg/kg/天剂量的靶标 attainment 概率超过90%。

核心结论

  • 多黏菌素B的剂量调整需考虑感染病原体的MIC。
  • 当MIC<0.5 mg/L时,当前儿科多黏菌素B给药方案可能可接受。

研究设计与样本

  • 研究纳入19例儿科患者接受静脉多黏菌素B(1.33-2.53 mg/kg/天),中位年龄12.5(范围3.2-17.8)岁。
  • 在稳态采集系列血浆样本,采用群体药代动力学分析建模。
  • 同时评估多黏菌素B治疗的临床疗效和肾毒性。

主要发现

  • 药代动力学数据由一阶消除的二室模型充分描述,体重是多黏菌素B清除率的显著协变量。
  • 临床成功14/19例(73.7%),仅1例患者发生急性肾损伤。
  • 28天死亡率为10.5%(2/19)。
  • 稳态多黏菌素B暴露为36.97±9.84 mg·h/L,低于50-100 mg·h/L的治疗暴露。
  • 以AUC24h/MIC目标为50时,当MIC<0.5 mg/L,1.5-3.0 mg/kg/天剂量的靶标 attainment 概率超过90%。

关键数值与推荐

  • 临床成功14/19例(73.7%)。
  • 急性肾损伤1例。
  • 28天死亡率10.5%(2/19)。
  • 稳态暴露36.97±9.84 mg·h/L,低于治疗暴露50-100 mg·h/L。
  • AUC24h/MIC目标为50时,MIC<0.5 mg/L下1.5-3.0 mg/kg/天剂量靶标 attainment 概率超过90%。

临床怎么用

  • 多黏菌素B的剂量调整需考虑感染病原体的MIC。
  • 当MIC<0.5 mg/L时,当前儿科多黏菌素B给药方案可能可接受。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current polymyxin B dosing in children relies on scant data. OBJECTIVES: To build a population pharmacokinetic (PK) model for polymyxin B in paediatric patients and assess the likely appropriateness of different dosages. METHODS: A total of 19 paediatric patients were enrolled to receive intravenous polymyxin B (1.33-2.53 mg/kg/day), and the median age was 12.5 (range 3.2-17.8) years. Serial plasma samples were collected at steady-state and modelled by population PK analysis. Clinical efficacy and nephrotoxicity of polymyxin B treatment were also assessed. RESULTS: PK data were adequately described by a two-compartment model with first-order elimination, and weight was a significant covariate of polymyxin B clearance. Clinical success occurred in 14 of 19 patients (73.7%) and only one patient developed acute kidney injury. The 28 day mortality was 10.5% (2/19). The steady-state polymyxin B exposure was 36.97 ± 9.84 mg·h/L, lower than the therapeutic exposure of 50-100 mg·h/L. With the AUC24h/MIC target of 50, the dosage of 1.5-3.0 mg/kg/day had a probability of target attainments over 90% when MICs were <0.5 mg/L. CONCLUSIONS: Dose adjustment of polymyxin B needs to consider the MIC of infecting pathogens. Current polymyxin B dosing for paediatric patients may be acceptable when MICs are <0.5 mg/L.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Wang PL, Liu P, Zhang QW, et al. Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother. 2022. PMID: 35924405. doi:10.1093/jac/dkac265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。